Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

28 questions · 28 findings · 2 reviews · Musculoskeletal

No studies found 5 · 17.9%GRADE not reported 0 · 0%Very low 7 · 25%Low 6 · 21.4%Moderate 10 · 35.7%High 0 · 0%

Cyclophosphamide vs methylprednisolone

Response to treatment (20% improvement)* · patients with neuropsychiatric involvement in systemic lupus erythematosus

It is very uncertain whether cyclophosphamide changes response to treatment (20% improvement)* compared with methylprednisolone (very low certainty).

1 finding from 1 review

Cyclophosphamide vs methylprednisolone

Urinary tract infection · patients with neuropsychiatric involvement in systemic lupus erythematosus

It is very uncertain whether cyclophosphamide changes adverse events ‐ Urinary tract infections compared with methylprednisolone (very low certainty).

1 finding from 1 review

Cyclophosphamide vs methylprednisolone

Adverse events ‐ Death · patients with neuropsychiatric involvement in systemic lupus erythematosus

It is very uncertain whether cyclophosphamide changes adverse events ‐ Death compared with methylprednisolone (very low certainty).

1 finding from 1 review

Autologous myeloablative selective HSCT vs cyclophosphamide

Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis

Autologous myeloablative selective HSCT probably leads to higher skin thickness – mRSS Scale 0–51 in which a higher number is worse… compared with cyclophosphamide (moderate certainty).

1 finding from 1 review